Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer
| Autor: | Bernd Schmidt, Felipe Cardenal, Maria Dolores Pastor, Luis Paz-Ares, Cristina Razquin, Maria D. Lozano, Michael Fleischhacker, Luis M. Montuenga, Javier J. Zulueta, Javier Santos García, Daniel Ajona, Ernest Nadal, Ruben Pio, Maria J. Pajares |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
Pathology Lung Neoplasms Gastroenterology Cohort Studies Complement Activation Multidisciplinary medicine.diagnostic_test Middle Aged respiratory system Prognosis 3. Good health Bronchial fluids Cohort Carcinoma Squamous Cell Adenocarcinoma Medicine Female medicine.symptom Lung cancer Bronchoalveolar Lavage Fluid Cohort study Research Article Adult medicine.medical_specialty Science Complement C5a Antigens Neoplasm Internal medicine Bronchoscopy medicine Carcinoma Complement C4b Humans Aged Neoplasm Staging Keratin-19 business.industry Case-control study Sputum Esput medicine.disease Small Cell Lung Carcinoma Peptide Fragments respiratory tract diseases Bronchoalveolar lavage ROC Curve Case-Control Studies Càncer de pulmó business Biomarkers |
| Zdroj: | PLoS ONE, Vol 10, Iss 3, p e0119878 (2015) PLoS ONE Recercat. Dipósit de la Recerca de Catalunya instname Dipòsit Digital de la UB Universidad de Barcelona Dadun. Depósito Académico Digital de la Universidad de Navarra |
| Popis: | Molecular markers in bronchial fluids may contribute to the diagnosis of lung cancer. We previously observed a significant increase of C4d-containing complement degradation fragments in bronchoalveolar lavage (BAL) supernatants from lung cancer patients in a cohort of 50 cases and 22 controls (CUN cohort). The present study was designed to determine the diagnostic performance of these complement fragments (hereinafter jointly referred as C4d) in bronchial fluids. C4d levels were determined in BAL supernatants from two independent cohorts: the CU cohort (25 cases and 26 controls) and the HUVR cohort (60 cases and 98 controls). A series of spontaneous sputum samples from 68 patients with lung cancer and 10 controls was also used (LCCCIO cohort). Total protein content, complement C4, complement C5a, and CYFRA 21-1 were also measured in all cohorts. C4d levels were significantly increased in BAL samples from lung cancer patients. The area under the ROC curve was 0.82 (95% CI = 0.71-0.94) and 0.67 (95% CI = 0.58-0.76) for the CU and HUVR cohorts, respectively. In addition, unlike the other markers, C4d levels in BAL samples were highly consistent across the CUN, CU and HUVR cohorts. Interestingly, C4d test markedly increased the sensitivity of bronchoscopy in the two cohorts in which cytological data were available (CUN and HUVR cohorts). Finally, in the LCCCIO cohort, C4d levels were higher in sputum supernatants from patients with lung cancer (area under the ROC curve: 0.7; 95% CI = 0.56-0.83). In conclusion, C4d is consistently elevated in bronchial fluids from lung cancer patients and may be used to improve the diagnosis of the disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|